Quick Answer
Organon & Co. reported Cash and Equivalents of $574.00 million for fiscal year 2025.
Organon & Co. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $574.00M | -15.0% |
| 2024 | $675.00M | -2.6% |
| 2023 | $693.00M | -1.8% |
| 2022 | $706.00M | -4.2% |
| 2021 | $737.00M | +6041.7% |
| 2020 | $12.00M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $672.00M | -11.9% | +12.2% |
| June 30, 2025 | $599.00M | -14.9% | +9.5% |
| March 31, 2025 | $547.00M | -4.9% | -19.0% |
| December 31, 2024 | $675.00M | -2.6% | -11.5% |
| September 30, 2024 | $763.00M | +84.3% | +8.4% |
| June 30, 2024 | $704.00M | +116.0% | +22.4% |
| March 31, 2024 | $575.00M | +25.3% | -17.0% |
| December 31, 2023 | $693.00M | -1.8% | +67.4% |
- Organon & Co. showed a decrease of -15.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Organon & Co.’s cash and equivalents has grown by 4683.3% (from $12.00 million to $574.00 million).
- The most recent figure is from Organon & Co.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: